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 In the Red Section of this issue of the  American Journal of 
Gastroenterology , well-known specialists in their respective fi elds 
present highlights from gastroenterology research in Spain. Th ese 
reports illustrate how well-organized network collaborations 
could impact the scientifi c literature worldwide, as these col-
laborations are positioned at the frontier of knowledge and could 
reveal innovative approaches to the diagnosis and treatment of 
patients with digestive diseases. Th ese achievements are especially 
notable, given that they occurred during a serious worldwide eco-
nomic crisis that aff ected research in many countries, especially 
those that do not generally prioritize science ( 1,2 ).
 Most of the successes presented here were obtained under the 
umbrella of two national organizations. One is the CIBERehd, an 
acronym of the Spanish name “Centro de Investigation Biomédica 
en Red para Enfermedades Hepáticas y Digestivas” or “Biomedical 
Research Networking Center Consortium in Hepatic and Diges-
tive Diseases” in English. Th e CIBERehd ( http://www.ciberehd.
org ) is part of a larger entity known as “CIBER”, which has addi-
tional areas of interest focused on a variety of human diseases. 
Th e CIBER was initiated and organized by the National Institute 
of Health Carlos III ( http://www.eng.isciii.es ), in charge of coordi-
nating Spanish biomedical research. Th e CIBERehd is a “virtual” 
center, combining the eff orts of the best research groups in gastro-
enterology and hepatology across the country, and it funds, awards, 
and prioritizes collaborative research among the groups.
 Th e second organization may have even greater merit in this con-
text, and is known as the Asociación Española de Gastro enterología 
(AEG) ( http://www.aegastro.es ), also known as the “Spanish Asso-
ciation of Gastroenterology” in English. Th e AEG has promoted 
important network research collaborations joining the eff orts 
of many clinical research groups of diff erent sizes and capaci-
ties. Many of these groups are not yet included in the CIBERehd, 
which limits their capacity for funding. Th e AEG has several 
working groups (Esophagus-Stomach-Duodenum, GI Oncology, 
Endoscopy, Neuro-gastroenterology and Motility, Infl ammatory 
Bowel Diseases, Pancreas and Biliary Tree) and platforms and col-
laborates closely with other scientifi c organizations, including the 
Spanish Working Group on Crohn’s Disease and Ulcerative Colitis 
(GETECCU) with its registries and methodological unit, as well 
as the Spanish Pancreatic Club. In just 10 years, CIBER investiga-
tors have published >7200 articles in the top medical journals, and 
almost 2600 of them were related to CIBERehd. Th e AEG groups 
have published almost 300 studies over the same period, fi ft y 
of which have been published in Th e American Journal of Gastro-
enterology ( 3,4 ).
 One of the fi ve reports published in this special section illus-
trates two of the tools enabling this small miracle, the ENEIDA 
(Estudio Nacional en Enfermedad Infl amatoria intestinal sobre 
Determinantes genéticos y Ambientales) and the AEG-REDCap 
platforms. Adrian G. McNicholl and Javier P. Gisbert describe how 
“cost-zero” research in Spain combined with international com-
petitive pressure created a strong collaboration of independent 
support networks through researcher associations and societies, 
and how this collaboration has become one of the most important 
contributors to Spanish Gastroenterology. ENEIDA, created by 
GETECCU, is a nationwide, hospital-based registry and biobank 
of Infl ammatory Bowel Disease patients from 100 Spanish hos-
pitals. Th is database provides an infrastructure for the develop-
ment of multicenter studies of all types. Th e impact and success of 
ENEIDA has grown exponentially and has become an inspiration 
for other European organizations replicating this model. Th e other 
major platform is the AEG-REDCap, created by AEG within a con-
sortium agreement with Vanderbilt University ( 5 ). AEG-REDCap 
provides scientifi c methodological support and online data cap-
ture/management tools to over 50 projects, including more than 
200 databases and 1300 researchers. Th e success of this initiative 
inspired participation by many European researchers in this local 
Spanish platform. Th e European Registry on  Helicobacter pylori 
management is the best example of this success as well as the larg-
est international project, with over 25,000 cases already registered.
 In the pages that follow, Enrique Quintero and Antonio Gimeno-
García off er a perspective on colorectal cancer screening based on 
studies conducted in Europe in general, and Spain in particular. 
Much of that knowledge was again obtained within the collabora-
tive network of the GI Oncology group of AEG. Th is AEG working 
group has effi  ciently and successfully generated ongoing projects, 
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including the EPICOLON (estudio de la EPIdemiologia del cáncer 
de COLON) I and II as well as COLONPREV (COLON PREVen-
tion study), which have already resulted in important reports. Th e 
COLONPREV project ( 6 ) will be the fi rst RCT to provide 10-year 
mortality data, comparing colonoscopy and biennial FIT, as screen-
ing methods for intermediate risk populations over the age of 50. 
On the basis of the local and regional studies summarized in their 
report, Quintero and Gimeno–García conclude that under condi-
tions of universal access to our National public Health System and 
coming from a Spanish perspective, the current recommendations 
for colorectal cancer screening of fi rst-degree relatives of patients 
with colorectal cancer should be revised for individuals with only 
one index case in the family. In their view, the evidence currently 
supports that these patients should follow a similar screening strat-
egy as those classifi ed within the average-risk population, and that 
fecal immunological tests (FIT) should be off ered as an alternative 
to colonoscopy screening in this population.
 Enrique de Madaria reports another exciting outcome of net-
work collaboration for the study of pancreatic diseases in Spain. He 
presents four clinical multicenter studies based on basic research 
addressing the eff ect of statins in experimental pancreatitis, and 
suggests a potential role for these drugs in improving the disease 
course as well as several outcomes. Th e EST-CPRE study, a retro-
spective analysis of consecutive patients undergoing Endoscopic 
Retrograde Cholangiopancreatography (ERCP) in four centers 
in Spain, found that patients consuming statins had a 70% lower 
risk of post-ERCP acute pancreatitis. Th is result prompted the 
initiation of a pan-European prospective cohort study involving 
centers from Spain, Italy, Finland, Croatia, Sweden, and Roma-
nia to confi rm these results with the STARK study ( STA tins and 
 R is K of post-ERCP acute pancreatitis). Th e STAR-TREC trial is 
another collaborative study, involving centers from Spain, Peru, 
and Bolivia, aiming to investigate whether atorvastatin will be 
useful in the prevention of acute pancreatitis aft er ERCP. Finally, 
Madaria presents the  SIMBA trial, ( SIM vastatin in the prevention 
of recurrent acute pancreatitis, a triple- B lind, r A ndomized con-
trolled trial) designed to investigate the eff ectiveness of simvasta-
tin (40 mg daily) in decreasing the incidence of new episodes of 
AP in recurrent cases. Th is multicenter, randomized, triple-blind, 
placebo-controlled trial is focused on adult patients with at least 
2 episodes of AP. Fift een centers from Spain have joined SIMBA, 
and recruitment has already started ( 7 ).
 Th e European and especially the Spanish contribution to our 
understanding of Eosinofi lic Esophagitis (EoE), a relatively new 
diagnosis, has been notable over the last 5 years. Javier Molina 
and Alfredo Lucendo are two of the most important researchers in 
this area ( 8 ). Th eir studies have been conducted in Spain, and are 
now being projected within the United European Gastroentero-
logy (UEG) organization. Crucially, these studies have advanced 
the understanding that GERD and EoE are not mutually exclusive 
disorders, and that there is a clear EoE phenotype with complete 
remission on PPIs, with or without GERD. European studies have 
demonstrated that phenotypic, molecular, and mechanistic fea-
tures cannot distinguish between patients with EoE that do or do 
not respond to PPI. Th erefore, Molina and Lucendo conclude that 
PPI therapy responders should be included within the spectrum of 
EoE, suggesting novel questions requiring investigation with new 
compounds such as vonoprazan, the fi rst agent of a new class of 
potassium-competitive acid blockers.
 Th e last report comes from one of our most relevant investigators 
on functional disorders. Fermin Mearín provides a provocatively 
titled report on the specifi cally Spanish view of IBS. Fermín Mearin 
has conducted several studies within the AEG working group, and 
is one of the researchers most familiar with the perception of this 
disease by Spanish and European gastroenterologists ( 9 ). Despite 
living in a Mediterranean country and consuming a Mediterranean 
diet, Spanish people are not “immune” to IBS. We appear to have 
similar IBS subtypes as patients from other parts of the world, with 
small diff erences relative to Northern European Countries and the 
USA. Mearin also points out that Spanish IBS patients seek medi-
cal attention more frequently than patients from other countries. 
Th is may be due to our public and open access universal health 
systems, and could have a tremendous impact on costs. Clearly, the 
regional IBS perspective described by Dr. Mearin will be crucial for 
an improved understanding of this disease, and will open areas of 
research for those interested in functional disorders.
 Th ese are just some examples of the excellent research currently 
performed in Spain, and refl ected the experiences of hardworking 
doctors and scientists in harsh economic environments. One could 
imagine what they would accomplish under a better support from 
our national and regional institutions.
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